Identifying CDK4/6 as a potentially actionable target in the context of KRAS-mutant NSCLC brain metastasis, our work provides a foundation for developing treatments for KRAS-G12C/CDKN2A mutant brain metastatic patients. The gene discussed is CDKN2A; the disease is non-small cell lung carcinoma.